No long-term study has been done to determine whether patients, who were previously treated with low-dose macrolides, cyclines, or quinolones, for acute and/or chronic infection, have a reduced risk of developing Alzheimer’s or Parkinson’s disease. The same immortal pathogens can cause cardiovascular disease; and studies showed patients treated in the prior three years with azithromycin, clarithromycin, or quinolones, for any reason, had a significant reduction in acute heart attack, stroke, and cardiac death. Male patients with cardiac disease and a positive test for chlamydia pneumonia had improved endothelial function, after five weeks of azithromax.

It is important to determine if treatment with macrolides and cyclines, and the avoidance of penicillin, impacts the risk of developing Alzheimer’s or Parkinson’s disease; or the subsequent course and severity of these chronic diseases.